Free shipping on all orders over $ 500

WIN 62,577

Cat. No. M8853
WIN 62,577 Structure
Size Price Availability
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Non-peptide NK1 tachykinin receptor antagonist.

Chemical Information
Molecular Weight 437.58
Formula C29H31N3O
CAS Number 138091-43-7
Solubility (25°C) ethanol: 1.4 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Douglas A Schober, et al. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites

[2] Alfred A Lanzafame, et al. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors

[3] S Lazareno, et al. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors

[4] B H Duvilanski, et al. Interaction between substance P and TRH in the control of prolactin release

[5] L Seguin, et al. Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent

Related Products
Izeltabart

Izeltabart is a high-affinity humanized antibody targeting ADAM9. Izeltabart can be used as ADC Antibody for site-specific conjugation with Maytansinoid-based DM21-C to synthesize IMGC936, an Antibody-drug Conjugate with strong anti-cancer activity. IMGC936 exhibits cytotoxicity against ADAM9-positive human tumor cell lines and potent antitumor activity in xenograft tumor models.

Cofetuzumab

Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7.

Crizanlizumab

Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs).

M3554 (anti-GD2 ADC)

M3554 is a novel anti-GD2 ADC designed based on humanized ch14.18 anti-GD2 antibody. M3554 has anti-tumor activity.

OGT2115

OGT2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT2115 has anti-angiogenic properties (IC50 = 1 μM).

  Catalog
Abmole Inhibitor Catalog




Keywords: WIN 62,577 supplier, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.